Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

por Badri, Prajakta S., King, Jennifer R., Polepally, Akshanth R., McGovern, Barbara H., Dutta, Sandeep, Menon, Rajeev M.
Publicado 2015

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemog...

por Badri, Prajakta, Jiang, Xuemin, Borodovsky, Anna, Najafian, Nader, Kim, Jae, Clausen, Valerie A., Goel, Varun, Habtemariam, Bahru, Robbie, Gabriel J.
Publicado 2020

Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal...

por Badri, Prajakta, Jiang, Xuemin, Borodovsky, Anna, Najafan, Nader, Kim, Jae, Clausen, Valerie A., Goel, Varun, Habtemariam, Bahru, Robbie, Gabriel J.
Publicado 2022

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

por Chayama, Kazuaki, Notsumata, Kazuo, Kurosaki, Masayuki, Sato, Ken, Rodrigues, Lino, Setze, Carolyn, Badri, Prajakta, Pilot‐Matias, Tami, Vilchez, Regis A., Kumada, Hiromitsu
Publicado 2015

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria

por Gaya, Anna, Munir, Talha, Urbano‐Ispizua, Alvaro, Griffin, Morag, Taubel, Jorg, Bush, Jim, Bhan, Ishir, Borodovsky, Anna, Wang, Yue, Badri, Prajakta, Garg, Pushkal
Publicado 2023

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

por Badri, Prajakta S., Dutta, Sandeep, Wang, Haoyu, Podsadecki, Thomas J., Polepally, Akshanth R., Khatri, Amit, Zha, Jiuhong, Chiu, Yi-Lin, Awni, Walid M., Menon, Rajeev M.
Publicado 2015